| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0057 | AK123657 | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116 ,SW1116) | down-regulated | N/A | Functional experiments demonstrated three dysregulated lncRNAs, AK123657, BX648207 and BX649059 were required for efficient invasion and proliferation suppression in CRC cell lines. | 24809982 | Lnc2Cancer |
| EL0076 | AOC4P | colorectal cancer | N/A | colorectal cancer cells | N/A | interaction | UPAT interacts with and stabilizes the epigenetic factor UHRF1 by interfering with its β-transducin repeat-containing protein (TrCP)-mediated ubiquitination. UHRF1 up-regulates Stearoyl-CoA desaturase 1 and Sprouty 4, which are required for the survival of colon tumor cells. | 26768845 | |
| EL0227 | BANCR | colorectal cancer | chromatin immunoprecipitation; luciferase assays; RT-PCR | fentanyl-treated colorectal cancer (CRC) cells | up-regulated | expression | Fentanyl induced BANCR upregulation and Ets-1 downregulation in CRC cells. Further studies showed that Ets-1 negatively regulated BANCR expression via the deacetylation of histones H3 within BANCR promoter. Ets-1 overexpression inhibited fentanyl-induced effects that could be reversed by BANCR co-overexpression | 26296467 | |
| EL0227 | BANCR | colorectal cancer | qPCR, Western blot etc. | colorectal cancer tissue | up-regulated | N/A | The quantitative polymerase chain reaction results showed that BANCR was frequently overexpressed in cancer tissues and this overexpression was found to significantly correlate with lymph node metastasis and tumour stage. The ectopic expression of BANCR contributed to the migration of human CRC Caco-2 cells, whereas knockdown of BANCR inhibited the migration of the HCT116 cells in vitro. Further investigation into the underlying mechanisms responsible for the migratory effects revealed that BANCR induced the epithelial-mesenchymal transition (EMT) through an MEK/extracellular signal-regulated kinase-dependent mechanism as treatment with the MEK inhibitor, U0126 decreased migration and reversed the EMT in the BANCR-overexpressed HCT116 cells. | 25013510 | Lnc2Cancer |
| EL0227 | BANCR | colorectal cancer | qPCR, Western blot, knockdown etc. | colorectal cancer tissue, cell lines (SW480, HCT116, RQO, HT-29 etc.) | down-regulated | interaction | In this study, we show that BANCR expression was significantly down-regulated in colorectal cancer tissues compared with normal tissues, and overexpression of BANCR suppressed colorectal cancer cell growth in vitro and in vivo.Down_regulation of BANCR contributes to theproliferation of colorectal cancer cells,at least in part,through the regulation of p21 protein. | 25928067 | Lnc2Cancer |
| EL0252 | BX648207 | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116 ,SW1116) | down-regulated | N/A | Functional experiments demonstrated three dysregulated lncRNAs, AK123657, BX648207 and BX649059 were required for efficient invasion and proliferation suppression in CRC cell lines. | 24809982 | Lnc2Cancer |
| EL0267 | CAHM | colorectal cancer | qPCR, qMSP etc. | blood, colorectal cancer tissue | down-regulated | N/A | A reverse transcriptase-qPCR assay showed that CAHM RNA levels correlated negatively with CAHM % methylation, and therefore CAHM gene expression is typically decreased in CRC. Both the frequency of detection and the amount of methylated CAHM DNA released into plasma increased with increasing cancer stage. | 24799664 | Lnc2Cancer |
| EL0275 | CCAL | colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | interaction | We identified colorectal cancer-associated lncRNA (CCAL) as a key regulator of CRC progression. Patients whose tumours had high CCAL expression had a shorter overall survival and a worse response to adjuvant chemotherapy than patients whose tumours had low CCAL expression.Our results suggest that CCAL is a crucial oncogenic regulator involved in CRC tumorigenesis and progression. | 25994219 | Lnc2Cancer |
| EL0276 | CCAT1 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | interaction | The expression of IncRNA-CCAT1 in tumor tissue was significantly higher than that in normal para-carcinoma tissue, and the expression level of CCAT1 was significantly correlated with local infiltration depth , tumor staging, vascular invasion and CA19-9 level, it mediates the EMT process of colorectal cancer. | 26064266 | Lnc2Cancer |
| EL0276 | CCAT1 | colorectal cancer | qPCR, ISH etc. | cell lines (SW-480, HT-29, HT29, SW-480 etc.) | up-regulated | expression | Recently, colon cancer associated transcript 1 (CCAT1) lncRNA was found to be expressed in colorectal cancer (CRC) tumors but not in normal tissue. | 23416875 | LncRNADisease Lnc2Cancer |
| EL0276 | CCAT1 | colorectal cancer | qPCR, knockdown etc. | primary prostatecancer tissue | up-regulated | N/A | CARLo-5 is highly expressed in CRC-derived cell lines compared with normal colon-derived fibroblasts and CRC primary tissues compared with their matched normal adjacent tissues (NATs). In addition, CARLo-5 is highly expressed in prostate cancer (PC) tissues compared with their NATs. CARLo-5 is significantly correlated with the rs6983267 allele associated with increased cancer susceptibility. We also found the MYC enhancer region physically interacts with the active regulatory region of the CARLo-5 promoter, suggesting long-range interaction of MYC enhancer with the CARLo-5 promoter regulates CARLo-5 expression. | 24594601 | Lnc2Cancer |
| EL0277 | CCAT1-L | colorectal cancer | qPCR, in vitro knockdown etc. | cell lines (HT29, HCT116) | up-regulated | N/A | CCAT1-L plays a role in MYC transcriptional regulation and promotes long-range chromatin looping. Importantly, the CCAT1-L locus is located within a strong super-enhancer and is spatially close to MYC. Knockdown of CCAT1-L reduced long-range interactions between the MYC promoter and its enhancers. In addition, CCAT1-L interacts with CTCF and modulates chromatin conformation at these loop regions. | 24662484 | Lnc2Cancer |
| EL0278 | CCAT2 | colorectal cancer | qPCR, RIP etc. | CRC tissue, cell lines (COLO320DM, HCT116, RKO, HEK293 etc.) | up-regulated | N/A | Here, we report that CCAT2, a novel long noncoding RNA transcript (lncRNA) encompassing the rs6983267 SNP, is highly overexpressed in microsatellite-stable colorectal cancer and promotes tumor growth, metastasis, and chromosomal instability. Our results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer pathogenesis, and provide an alternative explanation on the SNP-conferred cancer risk. | 23796952 | Lnc2Cancer |
| EL0279 | CCAT3 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
| EL0280 | CCAT7 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | down-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
| EL0281 | CCAT8 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | down-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
| EL0305 | CRNDE | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116, HT29, LS174T etc.) | up-regulated | N/A | In colorectal cancer cells, we demonstrate that treatment with insulin and insulin-like growth factors (IGF) repressed CRNDE nuclear transcripts, including those encompassing gVC-In4. These repressive effects were negated by use of inhibitors against either the PI3K/Akt/mTOR pathway or Raf/MAPK pathway, suggesting CRNDE is a downstream target of both signaling cascades. | 24184209 | Lnc2Cancer |
| EL0305 | CRNDE | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | expression | An uncharacterized gene locus (Chr16:hCG_1815491), now named colorectal neoplasia differentially expressed (gene symbol CRNDE), is activated early in colorectal neoplasia. | 22393467 | LncRNADisease Lnc2Cancer |
| EL0305 | CRNDE | colorectal cancer | quantitative real-time | 142 CRC tissues and 142 paired adjacent nontumorous tissues | up-regulated | N/A | upregulation of lncRNA CRNDE-h was significantly correlated with large tumor size | 27042112 | |
| EL0329 | DANCR | colorectal cancer | qPCR etc. | colorectal cancer tissues and paired adjacent non-tumor tissues | up-regulated | expression | Our results showed that lncRNA DANCR expression was increased in CRC tissues compared with that in adjacent normal tissues (P<0.05). In addition, tumors with high lncRNA DANCR expression was correlated with TNM stage, histologic grade, and lymph node metastasis (P<0.05). Kaplan-Meier analysis showed that patients with high lncRNA DANCR expression had a shorter overall survival (OS) and disease-free survival (DFS) compared with the low lncRNA DANCR expression group (P<0.05). Moreover, in a multivariate Cox model, our results showed that lncRNA DANCR expression was an independent poor prognostic factor for both OS and DFS in CRC. | 26617879 | Lnc2Cancer |
| EL0355 | DQ786243 | colorectal cancer | quantitative real-time polymerase | CRC tissues and cell lines | up-regulated | N/A | DQ786243 is an oncogene | 26934980 | |
| EL0367 | EHHADH-AS1 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
| EL0368 | ELFN1-AS1 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
| EL0463 | AC004893.2 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
| EL0469 | AC022075.3 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
| EL0471 | LINC02446 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
| EL0474 | LINC02086 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | down-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
| EL0495 | FEZF1-AS1 | colorectal cancer | N/A | primary colorectal carcinoma (CRC) | up-regulated | N/A | the downregulation of FEZF1-AS1 expression significantly; FEZF1 knockdown also significantly suppressed CRC cell proliferation | 26848625 | |
| EL0514 | FTX | colorectal cancer | qPCR, knockdown etc | CRC and adjacent normal colorectal tissues, cell lines (HT-29, SW1116, SW480, COLO205) | up-regulated | expression | Long non-coding RNA FTX was significantly upregulated in colorectal cancer tissues, and low long non-coding RNA FTX expression was significantly correlated with differentiation grade, lymph vascular invasion, and clinical stage. Patients with high long non-coding RNA FTX showed poorer overall survival than those with low long non-coding RNA FTX. Multivariate analyses indicated that status of long non-coding RNA FTX was an independent prognostic factor for patients. Functional analyses showed that upregulation of long non-coding RNA FTX significantly promoted growth, migration, invasion, and increased colony formation in colorectal cancer cells. | 26629053 | Lnc2Cancer |
| EL0525 | GAS2L3 | colorectal cancer | microarray, qPCR, knockdown etc. | cell lines (HCT116 ,SW1116) | down-regulated | N/A | Functional experiments demonstrated three dysregulated lncRNAs, AK123657, BX648207 and BX649059 were required for efficient invasion and proliferation suppression in CRC cell lines. | 24809982 | Lnc2Cancer |
| EL0526 | GAS5 | colorectal cancer | qPCR, FCA etc. | CRC tissue | down-regulated | expression | The lower expression of GAS5 was significantly correlated with large tumor size, low histological grade and advanced TNM stage. Multivariate analyses revealed that GAS5 expression served as an independent predictor for overall survival. Further experiments revealed that overexpressed GAS5 significantly repressed the proliferation both in vitro and in vivo. | 25326054 | Lnc2Cancer |
| EL0556 | H19 | colorectal cancer | a case-control study | N/A | N/A | N/A | N/A | 27027436 | |
| EL0556 | H19 | colorectal cancer | Multivariate analyses | 83 CRC patients | up-regulated | N/A | overexpression of H19 promoted the proliferation of CRC cells; growth regulator | 26989025 | |
| EL0556 | H19 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | N/A | LOI of IGF2 correlated strongly with biallelic hypermethylation of a core of five CpG sites in the insulator region of IGF2/H19, which is a known CTCF-binding element. As this methylation-dependent LOI was present in both tumors and normal colonic mucosa, it is possible that hypermethylation creates a field defect predisposing to cancer. | 11120891 | Lnc2Cancer |
| EL0556 | H19 | colorectal cancer | qPCR, knockdown etc. | CRC tissue, cell lines ( HCT8, HT29, HCT116, SW620 etc.) | up-regulated | regulation | 91H was significantly overexpressed in cancerous tissue and CRC cell lines compared with adjacent normal tissue and a normal human intestinal epithelial cell line. Moreover, 91H overexpression was closely associated with distant metastasis and poor prognosis in patients with CRC, except for CNV of 91H. Multivariate analysis indicated that 91H expression was an independent prognostic indicator, as well as distant metastasis. 91H played an important role in the molecular etiology of CRC and might be regarded as a novel prognosis indicator in patients with CRC. | 25058480 | Lnc2Cancer |
| EL0556 | H19 | colorectal cancer | qPCR, RFLP-PCR etc. | CRC tissue | up-regulated | N/A | The results of the present study suggest that LOI of IGF2 is important in the carcinogenesis of CRC. Hypomethylation of the sixth CTCF-binding site in the DMR of IGF2/H19 is linked to LOI and the common IGF2-H19 enhancer competition model for IGF2 imprinting does not apply to human CRC. | 22427002 | Lnc2Cancer |
| EL0556 | H19 | colorectal cancer | qPCR, Western blot, Luciferase reporter assay, RIP etc. | CRC tissue, cell lines (SW620, HCT-116) | up-regulated | interaction | We found that H19 was highly expressed in mesenchymal-like cancer cells and primary CRC tissues. H19 modulated the expression of multiple genes involved in EMT by acting as a competing endogenous RNA, which may build up the missing link between the regulatory miRNA network, EMT progression and accelerates in vivo and in vitro tumor growth. | 26068968 | Lnc2Cancer |
| EL0571 | HIF2PUT | colorectal cancer | N/A | colorectal cancer (CRC) tissues | N/A | interaction | LncRNA-HIF2PUT small interfering RNA transfection resulted in decreased stemness genes expression, impaired colony formation, and spheroid formation ability, retarded migration, and invasion of the cells. | 26648739 | |
| EL0578 | HOTAIR | colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | regulation | Two of the lncRNAs, HOTAIR and a novel lncRNA, lncRNA-422 were confirmed in more samples. GSEA indicated that gene sets most correlated with them were those named up-regulated in KRAS-over, down-regulated in JAK2-knockout, down-regulated in PDGF-over and down-regulated in TBK1-knockout, all of which were cancer-related. Subsequently, GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer. | 25456707 | Lnc2Cancer |
| EL0578 | HOTAIR | colorectal cancer | N/A | N/A | N/A | expression | Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes | 22817756 | LncRNADisease |
| EL0578 | HOTAIR | colorectal cancer | N/A | N/A | N/A | expression | HOTAIR was proposed as a diagnostic marker in breast and colorectal cancer. Its depletion resulted in reduced invasiveness, and its expression level correlated with differentially regulated genes of the PRC2 complex. | 24531795 | LncRNADisease |
| EL0578 | HOTAIR | colorectal cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
| EL0578 | HOTAIR | colorectal cancer | qPCR etc. | colorectal cancer tissue, blood | up-regulated | regulation | HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. | 24583926 | LncRNADisease Lnc2Cancer |
| EL0578 | HOTAIR | colorectal cancer | qPCR, knockdown etc. | CRC tissue, (HEK293T, HCT116, SW480) | up-regulated | epigenetics | Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers.patients with high HOTAIR expression had a relatively poorer prognosis. | 21862635 | LncRNADisease Lnc2Cancer |
| EL0578 | HOTAIR | colorectal cancer | qPCR, knockdown etc. | CRC tissue | up-regulated | expression | Our study showed that genetic variants in HOTAIR were associated with risk of colorectal cancer and rs7958904 may act as a potential biomarker for predicting the risk of colorectal cancer. | 25432874 | Lnc2Cancer |
| EL0578 | HOTAIR | colorectal cancer | qPCR, Western blot, knockdown etc. | CRC tissue, cell lines (FHC, CCL244, HCT116, SW480, LOVO) | up-regulated | expression | Results showed that CRC patients had higher HOTAIR expression in tumor tissues compared with adjacent normal tissues. In vitro, downregulation of HOTAIR reduced proliferation, migration and invasiveness while enhanced apoptosis and radio-sensitivity of CRC cells. Taken together, our findings suggest that long non-coding RNA HOTAIR expression is closely associated with tumor invasion and radiosensitivity, indicating the potential role in diagnostics and therapeutics of CRC. | 26549670 | Lnc2Cancer |
| EL0578 | HOTAIR | colorectal cancer | the tumorigenicity of CD133(+)-shHOTAIR were evaluated by the MTT | CD133(+)CSCs cell | down-regulated | N/A | down-regulating the HOTAIR expression in CD133(+)CSCs could serve as a potential anti-cancer regimen to inhibit the invasiveness and metastasis of CRC CSCs | 27069543 | |
| EL0582 | HOTTIP | colorectal cancer | qPCR etc. | colorectal cancer samples and 21 adjacent non-malignant samples | up-regulated | expression | Our results indicated that lncRNA HOTTIP was highly expressed in CRC compared with adjacent non-malignant tissues (P<0.001), and positively correlated with T stage (T1-2 vs. T3-4, P = 0.001), clinical stage (I-II stages vs. III-IV stages, P = 0.003), and distant metastasis (absent vs. present, P = 0.014) in CRC patients. Furthermore, we also observed that increased lncRNA HOTTIP expression was an unfavorable prognostic factor in CRC patients (P = 0.001), regardless of T stage, distant metastasis and clinical stage. Finally, overexpression of lncRNA HOTTIP was supposed to be an independent poor prognostic factor for CRC patients through multivariate analysis (P = 0.017). | 26617875 | Lnc2Cancer |
| EL0582 | HOTTIP | colorectal cancer | qPCR, Western blot, knockdown etc. | CRC and adjacent non-tumor colorectal samples, cell lines (DLD-1, SW480, SW620, HCT116) | up-regulated | interaction | We found that overexpression of HOTTIP is correlated with an advanced pathological stage and a larger tumor size. Moreover, functional analyses revealed that the knockdown of HOTTIP expression by small interfering RNA (siRNA) or small hairpin RNA (shRNA) could inhibit cell proliferation and induce cell apoptosis. More importantly, we observed that HOTTIP knockdown induced a marked increase in the number of cells in the G0/G1 phase and a reduction in the number of cells in the S phase in both DLD-1 cells and SW480 cells. An in vivo experiment also revealed that the knockdown of HOTTIP inhibited tumor growth. Western blot and immunohistochemistry analyses indicated that HOTTIP potentially contributed to CRC cell growth partially through the silencing of p21 expression. | 26678886 | Lnc2Cancer |
| EL0600 | HULC | colorectal cancer | qPCR etc. | cell lines (HepG2, Hep3B, SKOV3 etc.) | up-regulated | expression | HULC expression is not confined to HCC, but also to those colorectal carcinomas that metastasize to the liver. | 19445043 | LncRNADisease Lnc2Cancer |
| EL0628 | KCNQ1OT1 | colorectal cancer | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT4: colorectal cancer). | 23660942 | LncRNADisease |
| EL0628 | KCNQ1OT1 | colorectal cancer | overexpression | colorectal cancer cells | up-regulated | N/A | β-catenin can promote KCNQ1OT1 transcription through direct binding to the KCNQ1OT1 promoter | 26868975 | |
| EL0628 | KCNQ1OT1 | colorectal cancer | qPCR, FISH etc. | CRC tissue, cell lines (FBS, DLD-1, HCT-15 etc.) | differential expression | epigenetics | epigenetic disruption | 16965397 | LncRNADisease Lnc2Cancer |
| EL0664 | LINC00659 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
| EL0674 | LINC00964 | colorectal cancer | qPCR etc. | CRC tissue | down-regulated | interaction | Furthermore, the authors observed that mRNA expression levels of LNC00964-3 were significantly lower in CRC tissues than in corresponding normal tissues. The current findings reveal the possibility that piR-015551 may be generated from LNC00964-3, which may be involved in the development of CRC | 25740697 | Lnc2Cancer |
| EL0681 | LINC01021 | colorectal cancer | RNA-seq, pSILAC, qPCR, Western Blot, Luciferase reporter assay etc. | cell line (SW480) | up-regulated | interaction | Ectopic LINC01021 expression inhibited proliferation in SW480 cells. | 26183718 | Lnc2Cancer |
| EL0683 | SLC44A3-AS1 | colorectal cancer | microarray, qPCR etc. | blood (plasma) | up-regulated | expression | The expression of three lncRNAs in plasma of CRC were all significantly higher than those in controls. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future. | 26328256 | Lnc2Cancer |
| EL0707 | LINC01617 | colorectal cancer | microarray, qPCR etc. | blood (plasma) | up-regulated | expression | The expression of three lncRNAs in plasma of CRC were all significantly higher than those in controls. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future. | 26328256 | Lnc2Cancer |
| EL0708 | LINC01618 | colorectal cancer | microarray, qPCR etc. | blood (plasma) of CRC tissue | up-regulated | expression | The expression of three lncRNAs in plasma of CRC were all significantly higher than those in controls. The three lncRNAs might be the potential biomarker for the tumorigenesis prediction of CRC in the future. | 26328256 | Lnc2Cancer |
| EL0710 | LINC01630 | colorectal cancer | qPCR etc. | colorectal cancer tissue | down-regulated | expression | The qRT-PCR results revealed the misregulation of these genes during tumorigenesis. Their relative expression levels were significantly lower in tumor tissues than adjacent tumor-free tissues. However, the analysis found no significant correlation between reduced expression of these genes | 26429648 | Lnc2Cancer |
| EL0710 | LINC01630 | colorectal cancer | Quantitativereal-time-PCR (qRT-PCR) | colorectal tissue | down-regulated | N/A | LOC100287225 expressed in the intestinal tissue | 27062707 | |
| EL0721 | LINC-PINT | colorectal cancer | microarray, qPCR, RIP etc. | cell lines (KrasLA2/+, Trp53LSL/LSL, Rosa26-CreERT2 etc.) | down-regulated | N/A | In this study, we have identified and characterized the lincRNA named Pint, abona fidep53 transcriptional target that acts as negative modulator of the p53 response.We found a significant downregulation of PINT in colorectal tumors compared with normal tissue, suggesting a potential role of the lincRNA as a tumor suppressor. Pint binds directly to PRC2, and is required for the targeting of PRC2 to specific genes for H3K27 tri-methylation and repression. Of the total number of genes affected by Pint inhibition, 39% were upregulated and 61% downregulated upon Pint knockdown. | 24070194 | Lnc2Cancer |
| EL0747 | LINC-ROR | colorectal cancer | qPCR, Western blot, knockdown etc. | cell lines (HT29, HRT-18) | up-regulated | interaction | we found that the expression of ROR was significantly increased in a series of tumor cells, whereas all of the negative controls remained weakly expressed. | 26169368 | Lnc2Cancer |
| EL0791 | lncRNA-422 | colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | regulation | Two of the lncRNAs, HOTAIR and a novel lncRNA, lncRNA-422 were confirmed in more samples. GSEA indicated that gene sets most correlated with them were those named up-regulated in KRAS-over, down-regulated in JAK2-knockout, down-regulated in PDGF-over and down-regulated in TBK1-knockout, all of which were cancer-related. Subsequently, GO analyses of most significantly correlated coding genes of HOTAIR and lncRNA-422 showed that these two lncRNAs may participate in carcinogenesis by regulating protein coding genes involved in special biological process relevant to cancer. | 25456707 | Lnc2Cancer |
| EL0799 | lncRNA-ATB | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | N/A | High lncRNA-ATB expression was significantly associated with greater tumor size, depth of tumor invasion, lymphatic invasion, vascular invasion, and lymph node metastasis. Additionally, levels of lncRNA-ATB expression were significantly higher in patients with hematogenous metastases. | 25750289 | LncRNADisease Lnc2Cancer |
| EL0833 | LOC652276 | colorectal cancer | microarray, qPCR etc. | cell lines (T29, SW480, RKO, Lovo, HCTll6) | differential expression | expression | The radiosensitivity order of these 5 cell lines from low to high (SF2 value from high to low) was HT29, SW480, RKO, Lovo, HCT116. Among them, expression levels of R05532, NR_015441 and NR_033374 were positively correlated with radiation resistance(all P<0.01),which may be used as the predictiv marker of radiosensitivity of coloretcal cancer cells. | 25421768 | Lnc2Cancer |
| EL0843 | LSINCT5 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (LoVo, Caco-2, DLD1,HCT-8, HCT-116) | up-regulated | N/A | The expression of LSINCT5 is significantly upregulated in gastrointestinal cancer tissues and cell lines relative to their normal counterparts. Increased LSINCT5 expression was correlated with a larger tumor size, deeper tumor depth, and advanced clinical stage. Gastric cancer (GC) and colorectal cancer (CRC) patients with higher LSINCT5 expression levels have worse disease-free survival (DFS) and disease-specific survival (DSS) rates. | 25526476 | LncRNADisease Lnc2Cancer |
| EL0853 | MALAT1 | colorectal cancer | microarray, qPCR, Western blot etc. | CRC tissue, cell lines (HCT116, SW480, SW620, LoVo, CaCo-2 etc.) | up-regulated | regulation | In the present study, we found that MALAT1 was up-regulated in human primary CRC tissues with lymph node metastasis. Knockdown of MALAT1 inhibited CRC tumor growth and metastasis. MALAT1 regulated at least 243 genes in CRC cells in a genome-wide expression profiling. Among these genes, PRKA kinase anchor protein 9 (AKAP-9) was significantly up-regulated at both mRNA and protein levels. AKAP-9 was highly expressed in CRC cells with metastatic potential and human primary CRC tissues with lymph node metastasis. | 25446987 | Lnc2Cancer |
| EL0853 | MALAT1 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (SW620, SW480 etc.) | differential expression | N/A | The 3' end of MALAT-1 is an important biological motif in the invasion and metastasis of CRC cells. | 21503572 | LncRNADisease Lnc2Cancer |
| EL0853 | MALAT1 | colorectal cancer | qPCR etc. | colorectal cancer tissue | up-regulated | regulation | The MALAT1 levels in cancerous tissues were 2.26 times higher than those measured in noncancerous tissues, and this difference was statistically significant. Based on their expression level of MALAT1, the patients were divided into a high MALAT1 expression group and a low expression group. Patients with tumours harbouring higher expression of MALAT1 showed a significantly worse prognosis with a HR of 2.863 for DFS and 3.968 for OS. Furthermore, patients with perineural invasion demonstrated significantly worse DFS and OS than those without perineural invasion. | 25031737 | Lnc2Cancer |
| EL0853 | MALAT1 | colorectal cancer | qPCR, in vitro knockdown, RIP etc. | cell lines (LoVo, HCT116 ) | up-regulated | N/A | We found that overexpression of MALAT1 could promote cell proliferation and migration in vitro, and promote tumour growth and metastasis in nude mice. In CRC, MALAT1 could bind to SFPQ, thus releasing PTBP2 from the SFPQ/PTBP2 complex. In turn, the increased SFPQ-detached PTBP2 promoted cell proliferation and migration. SFPQ critically mediated the regulatory effects of MALAT1. Moreover, in CRC tissues, MALAT1 and PTBP2 were overexpressed, both of which were associated closely with the invasion and metastasis of CRC. MALAT1 might be a potential predictor for tumour metastasis and prognosis.Furthermore, the interaction between MALAT1 and SFPQ could be a novel therapeutic target for CRC. | 25025966 | Lnc2Cancer |
| EL0853 | MALAT1 | colorectal cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | CRC tissue, cell lines (LoVo etc.) | up-regulated | N/A | Using in situ hybridization, we found there was higher expression of MALAT1 in the CRC than the adjacent normal colorectal tissue. We next conducted correlation analysis between MALAT1 expression and clinicopathological characteristics of CRC. A statistically significant association was observed between MALAT1 expression and extent of metastasis and invasion. In contrast to adjacent normal tissues, the MALAT1 expression in CRC tissues resected from patients with metastatic diseases was higher than those with no metastasis. | 24244343 | Lnc2Cancer |
| EL0861 | MEG3 | colorectal cancer | qPCR, Western blot, FCA etc. | CRC tissue | down-regulated | expression | The lower expression of MEG3 was remarkably correlated with low histological grade, deep tumor invasion, and advanced tumor node metastasis (TNM) stage. Multivariate analyses revealed that MEG3 expression served as an independent predictor for overall survival. Further experiments revealed that overexpressed MEG3 significantly inhibited CRC cell proliferation both in vitro and in vivo. MEG3 is involved in the development and progression of colorectal cancer by regulating cell proliferation and shows that MEG3 may be a potential diagnostic and prognostic target in patients with colorectal cancer. | 25636452 | Lnc2Cancer |
| EL0880 | MIR31HG | colorectal cancer | qPCR, Western blot, knockdown, IHC, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, DLD1, SW480, RKO, HT-29) | down-regulated | interaction | LOC554202 was significantly downregulated in cancerous tissues and CRC cell lines compared with adjacent normal tissue and a normal human intestinal epithelial cell line. Low LOC554202 expression was closely associated with advanced pathologic stage and a larger tumor size. The overexpression of LOC554202 decreased the cell proliferation and induced apoptosis in vitro and hindered tumorigenesis in vivo. LOC554202 regulated cell apoptosis partly through the activation of specific caspase cleavage cascades. | 26362196 | Lnc2Cancer |
| EL0932 | MNX1-AS1 | colorectal cancer | microarray, qPCR, Luciferase reporter assay etc. | CRC tissue, cell lines (HCT116, RKO, HT29, SW620 etc.) | up-regulated | expression | Of the seletced lncRNAs, four lncRNAs named CCAT3, CCAT4, CCAT5, and CCAT6 (also named MYCLo-2) are upregulated in CRC cell lines, and two lncRNAs named CCAT7 and CCAT8 are downregulated in CRC cell lines. MYC-regulated lncRNAs, named MYCLos. The MYC-regulated MYCLos may function in cell proliferation and cell cycle by regulating MYC target genes such as CDKN1A (p21) and CDKN2B (p15), suggesting new regulatory mechanisms of MYC-repressed target genes through lncRNAs. | 25663692 | Lnc2Cancer |
| EL0965 | ncNRFR | colorectal cancer | qPCR, Northern bolt, in vitro knockdown etc. | colonic epithelial cell tumor tissue | up-regulated | N/A | Stable overexpression of ncNRFR in non-transformed, conditionally immortalized mouse colonocytes results in malignant transformation, as determined by growth in soft agar and formation of highly invasive tumors in nude mice. Moreover, ncNRFR appears to inhibit the function of the tumor suppressor let-7. These results suggest precise regulation of ncNRFR is necessary for proper cell growth in the colonic crypt, and its misregulation results in neoplastic transformation. | 24045012 | Lnc2Cancer |
| EL0969 | NCRUPAR | colorectal cancer | qPCR, Immunohistochemistry etc. | CRC tissue | down-regulated | interaction | Our results indicated that the expression of ncRuPAR was significantly downregulated in CRC compared with paired adjacent nontumor tissues, but the level of PAR-1 mRNA in cancerous tissues was significantly higher than in adjacent normal areas. The expression of ncRuPAR was significantly correlated with lymph node metastasis, distant metastasis, Duck's stage, differentiation, and TNM stage and was potentially negatively associated with the mRNA levels and EI scores of PAR-1. | 25119598 | Lnc2Cancer |
| EL0973 | NEAT1 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | expression | Results showed that NEAT1 expression in colorectal cancer was up-regulated in 72.0% (172/239) cases compared with corresponding normal counterparts, and related to tumor differentiation, invasion, metastasis and TNM stage. | 26314847 | Lnc2Cancer |
| EL1007 | NPTN-IT1 | colorectal cancer | qPCR, Western blot, in vitro knockdown, RIP etc. | CRC tissue, cell lines (QSG-7701, LO2, SMMC-7721 etc.) | down-regulated | expression | Aberrant Expression of lncRNA-LET in Tumor Tissue. In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. | 23395002 | LncRNADisease Lnc2Cancer |
| EL1052 | PCAT1 | colorectal cancer | qPCR etc. | CRC tissue | up-regulated | N/A | Our results showed that PCAT-1 expression in CRC tissues was significantly upregulated compared with the matched normal tissues and the overexpression of PCAT-1 was found in 64 % (62/81) of CRC. In addition, there was a significant association between PCAT-1 expression and distant metastasis. More important, CRC patients with PCAT-1 higher expression have shown significantly poorer overall survival than those with lower PCAT-1 expression. In conclusion, our results suggest that high expression of PCAT-1 is involved in CRC progression and could be a novel biomarker of poor prognosis in patient with colorectal cancer. | 23640607 | Lnc2Cancer |
| EL1088 | PRNCR1 | colorectal cancer | PCR-RFLP etc. | CRC tissue | differential expression | N/A | In overall analyses, we found that the rs13252298 and rs1456315 were associated with significantly decreased risks of CRC. In stratification analyses, we found that CRC patients carrying the rs1456315G were likely to have a tumor size of greater than 5 cm (G vs. A: adjusted OR = 1.56, 95% CI: 1.10-2.23). Additionally, patients with the rs7007694C and rs16901946G had decreased risks to develop poorly differentiated CRC, whereas patients with the rs1456315G had an increased risk to develop poorly differentiated CRC. | 24330491 | Lnc2Cancer |
| EL1088 | PRNCR1 | colorectal cancer | qPCR, Flow cytometry assay etc. | CRC tissue, cell lines (SW620, HCT116, SW480, LoVo, HT29) | up-regulated | expression | PRNCR1 was significantly overexpressed in CRC tissues compared with the expression in adjacent tissues, with an average fold increase of 10.55. Additionally, a high level of PRNCR1 was associated with large tumor volume. Compared with the normal human colorectal epithelial cell line (FHC), PRNCR1 was upregulated in most CRC cell lines (HCT116, SW480, LoVo and HT 29). | 26530130 | Lnc2Cancer |
| EL1102 | PVT1 | colorectal cancer | microarray, qPCR, Western blot, knockdown etc. | CRC tissue, cell lines (RKO, HCT116 etc.) | up-regulated | N/A | CRC cells transfected with PVT-1 siRNA exhibited significant loss of their proliferation and invasion capabilities. In these cells, the TGFβ1 signalling pathway and apoptotic signals were significantly activated. In addition, univariate and multivariate analysis revealed that PVT-1 expression level was an independent risk factor for overall survival of colorectal cancer patients. | 24196785 | Lnc2Cancer |
| EL1104 | R05532 | colorectal cancer | microarray, qPCR etc. | cell lines (T29, SW480, RKO, Lovo, HCTll6) | differential expression | expression | The radiosensitivity order of these 5 cell lines from low to high (SF2 value from high to low) was HT29, SW480, RKO, Lovo, HCT116. Among them, expression levels of R05532, NR_015441 and NR_033374 were positively correlated with radiation resistance(all P<0.01),which may be used as the predictiv marker of radiosensitivity of coloretcal cancer cells. | 25421768 | Lnc2Cancer |
| EL1168 | RPL34-AS1 | colorectal cancer | microarray, qPCR etc. | CRC tissue | down-regulated | N/A | We found that RP11-462C24.1 expression level was lower in cancer tissues compared with adjacent normal samples. Furthermore, its expression level was lower in CRC patients with metastasis than those without metastasis. That is, RP11-462C24.1 expression level decreased as the malignant degree of CRC increased. In addition, low expression of RP11-462C24.1 significantly correlated with more distant metastasis. | 24908062 | Lnc2Cancer |
| EL1210 | SLC25A25-AS1 | colorectal cancer | microarray, qPCR etc. | cell lines (T29, SW480, RKO, Lovo, HCTll6) | differential expression | expression | The radiosensitivity order of these 5 cell lines from low to high (SF2 value from high to low) was HT29, SW480, RKO, Lovo, HCT116. Among them, expression levels of R05532, NR_015441 and NR_033374 were positively correlated with radiation resistance(all P<0.01),which may be used as the predictiv marker of radiosensitivity of coloretcal cancer cells. | 25421768 | Lnc2Cancer |
| EL1226 | SNHG16 | colorectal cancer | qPCR, knockdown etc. | CRC tissue, cell lines (LoVo, Caco-2, DLD1, SW620, SW480, HCT8, HCT116 etc.) | down-regulated | expression | Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. | 24519959 | LncRNADisease Lnc2Cancer |
| EL1289 | TCONS_00026506 | colorectal cancer | microarray, qPCR etc. | cell line (HCT116) | up-regulated | expression | To validate the microarray results, we randomly selected 6 differentially expressed lncRNAs (TCONS_00026506, ENST00000468960, NR_038990, ENST00000575202, ENST00000539009 and ENST00000544591) between CRR-HCT116 and parental HCT116 cells to confirm their expression levels by qPCR. Changes in lncRNA expression are involved in 5-FU-based CRR in CRC cells. | 25921151 | Lnc2Cancer |
| EL1336 | TINCR | colorectal cancer | N/A | CRC tissues and metastatic CRC cell lines | up-regulated | N/A | TINCR was reversely correlated with CRC progression | 27009809 | |
| EL1349 | TP53COR1 | colorectal cancer | limiting dilution and serial tumor formation assay | colorectal cancer stem cells | N/A | interaction | Large intergenic non-coding RNA p21 (lincRNA-p21) is a potent suppressor of stem-like traits of CSCs purified from both primary colorectal cancer (CRC) tissues and cell lines. Ad-lnc-p21-MRE significantly suppressed the self-renewal potential and tumorigenicity of CSCs in nude mice. | 26497997 | |
| EL1349 | TP53COR1 | colorectal cancer | qPCR, Western blot, knockdown etc. | CRC tissue, cell lines (SW1116, SW620, LS 174T, HT29, LOVO etc.) | down-regulated | regulation | LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. | 24573322 | LncRNADisease Lnc2Cancer |
| EL1365 | Trp53cor1 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (HCT-116 (p53t/t), HCT-116(p53-/-) etc.) | down-regulated | expression | One of them, lincRNA-p21, was regulated by p53 and contributed to apoptosis in mouse embryonic fibroblasts. | 24012455 | LncRNADisease Lnc2Cancer |
| EL1399 | TUG1 | colorectal cancer | quantitative real-time PCR | cultured representative CRC cell lines and 120 CRC patients | up-regulated | N/A | increased their colony formation, migration, and invasion in vitro | 26856330 | |
| EL1402 | TUSC7 | colorectal cancer | qPCR etc. | CRC tissue, cell lines (CaCO-2, HCT8, LoVo, CCC-HIE-2 etc.) | down-regulated | N/A | The relative expression levels of LOC285194 was significantly lower in tumor tissues (p<0.001) and colorectal cancer cell lines compared with adjacent normal tissues and normal intestinal mucous cell line. In addition, low expression of LOC285194 was correlated with larger tumor size, higher tumor stage (p=0.034), and more distant metastasis (p=0.046). Our data indicate that LOC285194 might be a novel prognostic indicator in colorectal cancer and may be a potential target for diagnosis and gene therapy. | 23680400 | Lnc2Cancer |
| EL1411 | uc.388 | colorectal cancer | qPCR etc. | CRC tissue | down-regulated | N/A | Expression levels of uc.73 (p = 0.0139) and uc.388 (p = 0.0325) were significantly decreased in CRC tissue, and uc.73 indicated a positive correlation with overall survival. The lower expression of uc.388 was associated with the distal location of CRC (p = 0.0183). Our preliminary results suggest that uc.73 and uc.388 could be potential diagnostic and prognostic biomarkers in CRC patients. | 22328099 | Lnc2Cancer |
| EL1412 | uc.73 | colorectal cancer | qPCR etc. | CRC tissue | down-regulated | N/A | Expression levels of uc.73 (p = 0.0139) and uc.388 (p = 0.0325) were significantly decreased in CRC tissue, and uc.73 indicated a positive correlation with overall survival. The lower expression of uc.388 was associated with the distal location of CRC (p = 0.0183). Our preliminary results suggest that uc.73 and uc.388 could be potential diagnostic and prognostic biomarkers in CRC patients. | 22328099 | Lnc2Cancer |
| EL1431 | UCA1 | colorectal cancer | in vitro and in vivo growth-promoting function | two CRC cohorts | up-regulated | N/A | UCA1 could sponge endogenous miR-204-5p and inhibit its activity | 27046651 | |
| EL1431 | UCA1 | colorectal cancer | microarray, qPCR, Luciferase reporter assay, knockdown etc. | CRC tissue, cell lines (HCT116, SW480, RKO, HCT8, LoVo etc.) | up-regulated | interaction | UCA1 was upregulated in CRC and the expression of UCA1 was statistically correlated with lymph node metastasis, distant metastasis and tumor stage. We also found that knockdown of UCA1 significantly suppressed cell proliferation and metastasis in CRC cells. Flow cytometry assays showed UCA1 silencing induced G0/G1 growth arrest and apoptosis of CRC cells. To further investigate the regulatory mechanisms of UCA1, we identified that Ets-2 bound to the UCA1 core promoter using luciferase assays. | 26238511 | Lnc2Cancer |
| EL1431 | UCA1 | colorectal cancer | qPCR etc. | colorectal cancer tissue, cell lines (CaCO-2, SW480, HCT116, LoVo etc.) | up-regulated | N/A | UCA1 levels were markedly increased in CRC tissues, and this high level of UCA1 expression was significantly correlated with larger tumour size, less differentiated histology and greater tumour depth.an important role for UCA1 in the molecular aetiology of CRC and suggest a potential application for UCA1 in CRC diagnosis, progression and therapy. | 24977734 | Lnc2Cancer |
| EL1453 | WISP1 | colorectal cancer | N/A | HCT116, HCT8, and SW480 colorectal cancer cells | up-regulated | expression | AK027294 down-regulation significantly inhibited colorectal cancer cells proliferation and migration, but promoted cell apoptosis (P < 0.05) | 26820130 | |
| EL1459 | XIST | colorectal cancer | microarray, FISH etc. | CRC tissue | differential expression | N/A | X inactive-specific transcript gene amplification has also been detected in microsatellite-unstable sporadic human CRC tissue when compared to matched normal colorectal epithelium. aCGH revealed distinct DNA copy number changes between sporadic CIN- and MIN-associated colorectal carcinomas. A differential role of these candidate oncogenes and tumor suppressor genes in tumor development and progression of sporadic CIN and MIN CRC is likely and may also be involved in the response or resistance to therapeutic interventions, such as shown for microsatellite instability and 5-FU. | 17143621 | Lnc2Cancer |
| EL1517 | ZFAS1 | colorectal cancer | qPCR, knockdown, Western blot, Northern blot, RIP, RNA pull-down assay etc. | CRC tissue, cell lines ( HCT116+/+ (p53 wild type), HCT116-/- (p53 knockout), HT-29, DLD-1(p53241F), Colo-206, CaCO-2, SW-837, SW-620) | up-regulated | interaction | We determined expression of 83 long non-coding RNAs (lncRNAs) and identified ZFAS1 to be significantly up-regulated in colorectal cancer (CRC) tissue. We observed significant increase in p53 levels and PARP cleavage in CRC cell lines after ZFAS1 silencing indicating increase in apoptosis. Our data suggest that ZFAS1 may function as oncogene in CRC by two main actions: (i) via destabilization of p53 and through (ii) interaction with CDK1/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. | 26506418 | Lnc2Cancer |